Quotes:
"While the Omicron variant impacted our short term financial results in Q4, we ended the year with a lot of momentum which we believe will yield strong long term results."
This should indicate that the Omicron effects will decrease during Q1. Remember this! This went both ways, that either the caregiver may have been ill or the person who would be offered care/ASL.
"We expect 2022 to be a transformational year and one that will yield record revenues and adjusted EBITDA."
Transformational year, also in EBITDA. Have confidence in this.
"The three acquisitions made during December were significant for the Company. As noted in previous press releases, these businesses were producing approximately $ 9.3 million in annualized revenues and more than $ 1.3 million in adjusted EBITDA. To date, these acquisitions have gone as planned and we have been pleased with the results. "
These figures show how much revenue will increase in the short term.
"Our acquisition pipeline continues to be full of compelling opportunities and it is our intention to act on several of these opportunities during the year. The demand for home care will continue to increase for several decades given the aging population demographics and it is our intention to position Nova Leap as a leader in the industry. "
Full pipeline, full demand.
"I will refer, as I have in the past, to insider buying. I believe, when insiders acquire shares of Nova Leap in the open market, that is a sign of the confidence they hold in our long term strategy and the trajectory of the During Q4, several insiders continued to acquire shares in the open market at prices well above the current price and insiders continue to hold more than 36% of the Company's outstanding shares. Again, I believe this demonstrates a meaningful commitment to the Company's long -term strategy and, as I have alluded to in past commentary, best aligns potential future outcomes with those responsible for making important decisions. ”
No comment needed.